In vitro evidence for a new therapeutic approach in renal cell carcinoma

13Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Purpose: Renal cell carcinoma (RCC) is the most lethal among the common urologic malignancies, comprising 3% of all human neoplasias; approximately 40% of patients eventually die of cancer progression. One third of patients who present with metastatic disease and up to 40% treated for localized disease generally experience recurrence. RCCs are characterized by high resistance to chemo-, radio- and immunotherapy. We recently discovered an endogenous enzymatic activity, which is particularly expressed in tumorigenic cell, endogenous non-telomerase reverse transcriptase (RT) of retrotrasposon/retroviral origin, as a specific target to induce proliferation arrest in a number of human carcinogenesis in vitro culture cell lines. Methods: To address this possibility, we have employed RCC primary cell culture testing pharmacological inhibition, in vitro by two characterized non nucleosidic RT inhibitors, nevirapine and efavirenz; next, we assessed morphological effects and analyzed putative modulation on gene expression profile. Results: Both treatments reduced cell proliferation rate and induced morphological differentiation and gene expression reprogramming in different RCC analyzed tumor biomarkers. Conclusion: In this study we describe a new potential therapeutic approach to obtain considerable future benefits in renal carcinoma cure and attempt to establish a new possible pharmacological therapy based on oral drugs administration in renal RCC treatment.

Cite

CITATION STYLE

APA

Pittoggi, C., Martis, G., Mastrangeli, G., Mastrangeli, B., & Spadafora, C. (2008). In vitro evidence for a new therapeutic approach in renal cell carcinoma. International Braz J Urol, 34(4), 492–502. https://doi.org/10.1590/S1677-55382008000400012

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free